Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma

  • Authors:
    • Shigeki Shimizu
    • Kazuko Sakai
    • Takaaki Chikugo
    • Takao Satou
    • Naoki Shiraishi
    • Tetsuya Mitsudomi
    • Kazuto Nishio
  • View Affiliations

  • Published online on: February 23, 2021     https://doi.org/10.3892/ol.2021.12582
  • Article Number: 320
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pulmonary sarcomatoid carcinoma (PSC) is classified as poorly differentiated, and non‑small cell lung carcinomas that contained a component of sarcoma or sarcoma‑like differentiation are rare. The underlying carcinogenetic mechanism governing PSC remains unclear. The current study investigated the underlying carcinogenetic mechanism of PSC based on the hypothesis that it involves the epithelial‑mesenchymal transition (EMT) process. Mutation analysis of PSCs, including carcinosarcoma, pleomorphic carcinoma and epithelial carcinoma specimens, was performed using targeted deep sequencing, whole transcriptome analysis and digital spatial profiling (DSP). PSCs exhibit a distinct mutation profile, with TP53, SYNE1 and APC mutations. Therefore, clustering of the gene expression profiles allowed the PSCs to be distinguished from the epithelial carcinomas. Increased gene expression of fibronectin in PSC was an important contributor to differential profiles. Pathway analysis revealed enhanced activity of the integrin‑linked kinase (ILK) signaling pathway in the PSCs. DSP analysis using 56 antibodies of marker proteins confirmed significantly higher expression of fibronectin in PSCs. Intratumor heterogeneity of fibronectin expression was observed in sarcoma components. In conclusion, epithelial‑mesenchymal transition process mediated by ILK signaling may be associated with carcinogenetic mechanisms of PSC. Overexpression of fibronectin mediated by ILK signaling appears to serve a role in the EMT involved in the PSC transformation process.
View Figures
View References

Related Articles

Journal Cover

April-2021
Volume 21 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shimizu S, Sakai K, Chikugo T, Satou T, Shiraishi N, Mitsudomi T and Nishio K: Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. Oncol Lett 21: 320, 2021
APA
Shimizu, S., Sakai, K., Chikugo, T., Satou, T., Shiraishi, N., Mitsudomi, T., & Nishio, K. (2021). Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. Oncology Letters, 21, 320. https://doi.org/10.3892/ol.2021.12582
MLA
Shimizu, S., Sakai, K., Chikugo, T., Satou, T., Shiraishi, N., Mitsudomi, T., Nishio, K."Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma". Oncology Letters 21.4 (2021): 320.
Chicago
Shimizu, S., Sakai, K., Chikugo, T., Satou, T., Shiraishi, N., Mitsudomi, T., Nishio, K."Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma". Oncology Letters 21, no. 4 (2021): 320. https://doi.org/10.3892/ol.2021.12582